Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Falling through the cracks: a qualitative study of HIV risks among women who use drugs and alcohol in Northeast India

Autor: Kermode Michelle, Sono Collins Z, Songput Chingzaning Hangzo, Devine Alexandra

Publikováno v: BMC International Health and Human Rights, Vol 13, Iss 1, p 9 (2013)

Abstract Background HIV risks for women who inject drugs and those who engage in sex work are well documented. Women who are dependent on non-injecting drugs and alcohol are also likely to have increased vulnerability to HIV infection, but until they

Externí odkaz: https://doaj.org/article/cdf9909bde8c45db9d7d785ba8e2bc16

Some peace of mind: assessing a pilot intervention to promote mental health among widows of injecting drug users in north-east India

Autor: Dzuvichu Bernice, Chandra Prabha, Devine Alexandra, Kermode Michelle, Gilbert Thomhood, Herrman Helen

Publikováno v: BMC Public Health, Vol 8, Iss 1, p 294 (2008)

Abstract Background HIV prevalence in north-east India is high and injecting drug use (IDU) is common. Due to HIV-related deaths there are increasing numbers of IDU widows, many of whom are HIV infected, and experiencing poor health, social isolation

Externí odkaz: https://doaj.org/article/7fb8dcdc24ec45ecac2a0619f1cde0d3

Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade.

Autor: Gstalder C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Population Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Miao D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Lutterbach B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., DeVine AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Lin C; Department of Molecular Genetics, The Ohio State University, Columbus, Ohio., Shettigar M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Pancholi P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Carter SL; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Division of Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Manos MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Rojas-Rudilla V; Department of CAMD Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Brennick R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Gjini E; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Chen PH; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Lako A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Rodig S; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Yoon CH; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Miles W; Department of Molecular Genetics, The Ohio State University, Columbus, Ohio., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Haq R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. rizwan_haq@dfci.harvard.edu.; Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2020 Sep; Vol. 10 (9), pp. 1296-1311. Date of Electronic Publication: 2020 May 05.

Overcoming reprogramming resistance of Fanconi anemia cells.

Autor: Müller LU; Division of Pediatric Hematology/Oncology, Children's Hospital Boston, and Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA., Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park IH, London WB, Strait K, Schlaeger T, Devine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA

Publikováno v: Blood [Blood] 2012 Jun 07; Vol. 119 (23), pp. 5449-57. Date of Electronic Publication: 2012 Feb 27.